How strong is the evidence for stem-cell therapy in Arterial Hypertension?
ClinicalTrials.gov registrations alone cannot establish how strong the evidence is. Registry activity is relatively mature, with multiple Phase 3/4 registrations: the registry holds 35 records, 17 completed, 5 at Phase 3 or 4, and 2 stopped early (6%). MSC-specific work accounts for 11 of those records. These counts describe research activity and maturity, not benefit, safety or certainty. Snapshot 2026-08-29.
What counts as a real result in Arterial Hypertension
Credible evidence uses 24-hour ambulatory readings, not clinic cuffs, over months rather than weeks, with medication changes documented. The real endpoint is cardiovascular events; surrogate pressure changes are only a starting point, and a single reading after an infusion is noise.
What we can say from registrations alone
- Volume: 35 registered studies since 2001.
- Maturity: 5 confirmatory-phase records.
- Delivery: 17 completed; 2 terminated, withdrawn or suspended.
- Scale: median planned enrolment 46 participants, largest 500.
The completed studies
Completed does not mean published, and published does not mean positive. These are the finished records — the starting point for checking whether results ever appeared.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT03562715 — microRNAs Role in Pre-eclampsia Diagnosis | n/a | Completed | 200 | Cairo University | 2016-11-28 |
| NCT00013975 — Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease | n/a | Completed | 120 | National Heart, Lung, and Blood Institute (NHLBI) | 2001-03 |
| NCT00641836 — Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension | n/a | Completed | 98 | Zhejiang University | 2005-07 |
| NCT01041287 — Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells | Phase 4 | Completed | 96 | Emory University | 2009-12 |
| NCT02266394 — Hypoxia and Inflammatory Injury in Human Renovascular Hypertension | Phase 1 | Completed | 42 | Mayo Clinic | 2014-10-21 |
| NCT02937922 — Effect of Exercise on Endothelial Injury in Hypertensive Patients | n/a | Completed | 33 | Instituto de Cardiologia do Rio Grande do Sul | 2016-01 |
What registrations cannot tell you
Whether results were positive. Whether they were published at all — a large share of registered studies never report outcomes, which biases what the literature appears to show. And whether the product a commercial clinic sells resembles the product studied: cell source, dose, processing and delivery route vary enormously between a registered protocol and an off-protocol injection.
How to use this when someone is selling you a treatment
Ask which specific registered study supports the offer, then compare its intervention description with your quote. If the answer is a general gesture at "Arterial Hypertension research", you are being sold the field's activity rather than evidence about the product. The Provider Question Builder turns that gap into questions.
Frequently asked
How strong is the evidence for stem-cell therapy in Arterial Hypertension?
ClinicalTrials.gov registrations alone cannot establish how strong the evidence is. Registry activity is relatively mature, with multiple Phase 3/4 registrations: 35 registered records, 5 at Phase 3/4 and 2 stopped early (2026-08-29).
Has any stem-cell product been approved for this condition?
Look it up at source: regulators publish authorised products and indications. Registration of a trial, a licence to operate a clinic and product approval are three different things.
Why do clinics cite hundreds of studies?
Because the registry is public and impressive-looking. What it cannot show — published, controlled outcomes for the exact product — is the part that decides the question.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Arterial Hypertension: cell-therapy evidence and registered trials
- How much does stem cell therapy for Arterial Hypertension cost? (2026)
- Arterial Hypertension stem cell therapy — your questions answered (2026)
- Arterial Hypertension: cell-therapy evidence by therapy class
- MSC vs exosomes for Arterial Hypertension: what the registries show